Patents by Inventor Lee Patient

Lee Patient has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof
    Publication number: 20230110165
    Abstract: Compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof, that are inhibitors of SSAO activity: where V, W, X, Y, Z, R1, and R3 are as defined herein.
    Type: Application
    Filed: October 7, 2022
    Publication date: April 13, 2023
    Inventors: Max Espensen, Lee Patient, David Evans, Edward Savory, Iain Simpson
  • Imidazo[4,5-C]pyridine derived SSAO inhibitors
    Patent number: 11530208
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof and the use of the same in therapy: wherein Z, Y, R1, W, V, and R3 are as defined in claim 1.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: December 20, 2022
    Assignee: PROXIMAGEN, LLC
    Inventors: Lee Patient, Iain Simpson, Edward Savory
  • Substituted imidazo[4,5-c]pyridine compounds and compositions thereof
    Patent number: 11512082
    Abstract: Compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof, that are inhibitors of SSAO activity: where V, W, X, Y, Z, R1, and R3 are as defined herein.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: November 29, 2022
    Assignee: Proximagen, LLC
    Inventors: Max Espensen, Lee Patient, David Evans, Edward Savory, Iain Simpson
  • CXCR4 Receptor Antagonists
    Publication number: 20220348577
    Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.
    Type: Application
    Filed: March 2, 2021
    Publication date: November 3, 2022
    Inventors: Giles Brown, Michael Higginbottom, Alison Stewart, Lee Patient, Allison Carley, Iain Simpson, Edward Daniel Savory, Kathryn Oliver, Andrew Graham Cole
  • CXCR4 receptor antagonists
    Patent number: 10995091
    Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: May 4, 2021
    Assignee: Proximagen LLC
    Inventors: Edward Daniel Savory, Alison Stewart, Allison Carley, Giles Brown, Iain Simpson, Kathryn Oliver, Lee Patient, Michael Higginbottom, Andrew Graham Cole
  • Process for the preparation of (3S,4S)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3H-imidazo[4,5-C]pyridine-5(4H)-carboxylate
    Patent number: 10988473
    Abstract: The invention relates to an improved process for the synthesis of (3S, 4S)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3H-imidazo[4,5-c]pyridine-5(4H)-carboxylate, and pharmaceutically acceptable salts thereof, such as the methanesulphonic acid salt.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: April 27, 2021
    Assignee: BENEVOLENTAl CAMBRIDGE LIMITED
    Inventors: Viet-Anh Anne Horgan, Olof Haglund, Lee Patient, Edward Savory, Michael Higginbottom, Michael Ashwood
  • Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors
    Patent number: 10968223
    Abstract: A process for the preparation of a compound of formula (Ia) or a pharmaceutically acceptable salt, or N-oxide thereof that includes reacting a compound of formula (IIIa) or (Va) with a compound of formula (IX) to form the compound of formula (Ia)
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: April 6, 2021
    Assignee: Proximagen, LLC
    Inventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
  • THERAPEUTIC COMPOUND AND USE IN THERAPY
    Publication number: 20210024518
    Abstract: {4-[3-(Dimethylamino)propoxy]phenyl}methyl (4S)-4-(propan-2-yl)-3H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carboxylate, and pharmaceutically or veterinarily acceptable salts thereof.
    Type: Application
    Filed: August 5, 2020
    Publication date: January 28, 2021
    Inventor: Lee Patient
  • IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS
    Publication number: 20200347059
    Abstract: A process for the preparation of a compound of formula (Ia) or a pharmaceutically acceptable salt, or N-oxide thereof that includes reacting a compound of formula (IIIa) or (Va) with a compound of formula (IX) to form the compound of formula (Ia)
    Type: Application
    Filed: July 20, 2020
    Publication date: November 5, 2020
    Applicant: PROXIMAGEN, LLC
    Inventors: Max ESPENSEN, Lee PATIENT, David EVANS, Iain SIMPSON, Edward SAVORY
  • Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors
    Patent number: 10766897
    Abstract: The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: September 8, 2020
    Assignee: PROXIMAGEN, LLC
    Inventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
  • COMPOUNDS
    Publication number: 20200262835
    Abstract: Compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof, that are inhibitors of SSAO activity: where V, W, X, Y, Z, R1, and R3 are as defined herein.
    Type: Application
    Filed: February 7, 2020
    Publication date: August 20, 2020
    Applicant: PROXIMAGEN, LLC
    Inventors: Max ESPENSEN, Lee PATIENT, David EVANS, Edward SAVORY, Iain SIMPSON
  • Therapeutic compound and use in therapy
    Patent number: 10738044
    Abstract: {4-[3-(Dimethylamino)propoxy]phenyl}methyl (4S)-4-(propan-2-yl)-3H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carboxylate, and pharmaceutically or veterinarily acceptable salts thereof.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: August 11, 2020
    Assignee: PROXIMAGEN, LLC
    Inventor: Lee Patient
  • Compounds
    Patent number: 10590125
    Abstract: The present invention relates to compounds which are inhibitors of SSAO activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: March 17, 2020
    Assignee: PROXIMAGEN, LLC
    Inventors: Max Espensen, Lee Patient, David Evans, Edward Savory, Iain Simpson
  • PROCESS FOR THE PREPARATION OF (3S,4S)-TETRAHYDROFURAN-3-YL 4-ISOPROPYL-6,7-DIHYDRO-3H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-CARBOXYLATE
    Publication number: 20200062746
    Abstract: The invention relates to an improved process for the synthesis of (3S,4S)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3H-imidazo[4,5-c]pyridine-5(4H)-carboxylate, and pharmaceutically acceptable salts thereof, such as the methanesulphonic acid salt.
    Type: Application
    Filed: October 25, 2017
    Publication date: February 27, 2020
    Applicant: Benevolentai Cambridge Limited
    Inventors: Anne HORGAN, Olof HAGLUND, Lee PATIENT, Edward SAVORY, Michael HIGGINBOTTOM, Michael ASHWOOD
  • IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS
    Publication number: 20200002335
    Abstract: The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.
    Type: Application
    Filed: August 16, 2019
    Publication date: January 2, 2020
    Applicant: PROXIMAGEN, LLC
    Inventors: Max ESPENSEN, Lee PATIENT, David EVANS, Iain SIMPSON, Edward SAVORY
  • Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors
    Patent number: 10428066
    Abstract: The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: October 1, 2019
    Assignee: PROXIMAGEN, LLC
    Inventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
  • NEW THERAPEUTIC COMPOUND AND USE IN THERAPY
    Publication number: 20190185467
    Abstract: {4-[3-(Dimethylamino)propoxy]phenyl}methyl(4S)-4-(propan-2-yl)-3H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carboxylate, and pharmaceutically or veterinarily acceptable salts thereof.
    Type: Application
    Filed: July 21, 2016
    Publication date: June 20, 2019
    Applicant: PROXIMAGEN LIMITED
    Inventor: Lee PATIENT
  • CXCR4 RECEPTOR ANTAGONISTS
    Publication number: 20190062333
    Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.
    Type: Application
    Filed: October 22, 2018
    Publication date: February 28, 2019
    Applicant: Proximagen, LLC
    Inventors: Edward Daniel SAVORY, Alison STEWART, Allison CARLEY, Giles BROWN, Iain SIMPSON, Kathryn OLIVER, Lee PATIENT, Michael HIGGINBOTTOM, Andrew Graham COLE
  • CXCR4 receptor antagonists
    Patent number: 10155761
    Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: December 18, 2018
    Assignee: PROXIMAGEN, LLC
    Inventors: Edward Daniel Savory, Alison Stewart, Allison Carley, Giles Brown, Iain Simpson, Kathryn Oliver, Lee Patient, Michael Higginbottom, Andrew Graham Cole
  • Substituted imidazo[4,5-c]pyridines as SSAO inhibitors
    Patent number: 10065954
    Abstract: Specific compounds of formula (Ia): and pharmaceutically acceptable salts thereof. Pharmaceutical compositions of the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof. A method for inhibiting tumor growth in a subject that includes administering to the subject an effective amount of a compound selected from the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof. A method for modulating semicarbazide-sensitive amine oxidase activity in a subject that includes administering to the subject an effective amount of a compound selected from the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: September 4, 2018
    Assignee: PROXIMAGEN LIMITED
    Inventors: Max Espensen, Lee Patient, Edward Savory